After more than 20 years contributing to the world’s leading stem cell research companies, Dr. Melissa Carpenter founded Carpenter Group Consulting in 2008. Throughout her distinguished career, she has made many significant contributions to stem cell research and therapy development.

From exploring new technologies and translating them into therapies to navigating complex regulatory hurdles, Dr. Melissa Carpenter’s stem cell experience is as broad as it is deep. She is a pioneer in the human embryonic stem cell (hESC) research field and is one of the few practicing professionals with a background in this highly specialized industry.

Dr. Carpenter has held leadership positions at CytoTherapeutics, Inc., Geron Corporation and Novocell, Inc., where she built critical therapy development programs from the ground up. Under her leadership, the companies realized significant innovations, many of which are moving ever closer to becoming approved regenerative therapies.

VP of Research and Development at Novocell, Inc. (now Viacyte, Inc.)
Led the discovery research team that developed the differentiation protocols for pancreatic progenitor cells that have become the standard in the stem cell field. Translated the research program to preclinical development and created the regulatory strategy for the delivery of an encapsulated hESC-derived product into diabetes patients.

Principal Investigator and Scientist at the Robarts Research Institute and Associate Professor, Faculty of Medicine at the University of Western Ontario
Focused on the epigenetic status of undifferentiated human embryonic stem cells and the signaling mechanisms involved in self-renewal.

Director of Stem Cell Biology at Geron Corporation
Established, built and managed discovery research and preclinical programs aimed at developing therapies for Parkinson’s disease, spinal cord injury, cardiac disease, liver disease and diabetes.

Scientist at CytoTherapeutics, Inc. (now StemCell, Inc.)
Derived, characterized and processed the first human neural stem cells, a technology that is now in phase 1 and 2 clinical trials for the treatment of Batten disease, Pelizaeus-Merzbacher disease, spinal cord injury and age-related macular degeneration.

Earned a Ph.D. in the Laboratory of Cellular and Molecular Neurobiology at the University of California, Irvine.

Full CV available upon request.